ORLANDO, Fla. — The glucagon-like peptide 1 (GLP-1) receptor agonist semaglutide (Wegovy, Ozempic) reduced cardiovascular events and reduced the risk of progression to diabetes by 73% […]

ORLANDO, Fla. — Patients with type 1 and 2 diabetes who delay treatment with recommended statin therapy to address the well-known high risk for cardiovascular (CV) […]

ORLANDO, Fla. — The old, generic cholesterol drug fenofibrate has shown potential for slowing the progression of diabetic retinopathy in people with early retinal changes, with […]

ORLANDO, FL — Continuous glucose monitoring (CGM) of hospitalized patients with diabetes could provide early and important clues about changing insulin needs and reduce the need […]

Weight loss achieved through bariatric surgery lowered the risk of major adverse cardiovascular events (MACE) by 42% and all-cause mortality by 37% in people who were […]

ORLANDO, FL — The diabetes and weight loss drug tirzepatide (Mounjaro for type 2 diabetes; Zepbound for obesity) was so effective at reducing sleep disruptions in […]

SAN DIEGO, California — A review of prescription patterns reveals calcitonin gene-related peptide (CGRP) and gepant medications for migraine reveals significant gender and racial disparities that […]